Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20707028 | 0.81 | — | — | |
| SCHEMBL19388306 | 0.79 | TSHR (0.33) | TSHR | |
| SCHEMBL12086289 | 0.76 | KDM4E (0.35) | TSHR | |
| SCHEMBL14376297 | 0.76 | KDM4E (0.35) | TSHR | |
| SCHEMBL5207103 | 0.74 | TSHR (0.33) | TSHR | |
| SCHEMBL20047471 | 0.72 | — | — | |
| SCHEMBL4268119 | 0.71 | — | — | |
| SCHEMBL10066634 | 0.70 | CYP2C9 (0.45) | TSHR | |
| SCHEMBL12404657 | 0.70 | CNR2 (0.39) | TSHR | |
| SCHEMBL25583790 | 0.70 | CYP2C9 (0.45) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220018849-A1 | SERINE HYDROLASE PROFILING ASSAY IN BIOTHERAPEUTICS | MERCK SHARP & DOHME LLC | 2022-01-20 | — | — | US | disclosed |
| US-20180079726-A1 | BENZIMIDAZOLE DERIVATIVES AND USE THEREOF | PURDUE PHARMA LP (US) | 2018-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180079726-A1 | BENZIMIDAZOLE DERIVATIVES AND USE THEREOF | TRPV1, TRPV4, KCNA4 | TSHR 3302/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.